Asthma-COPD Overlap
On this page
Direct answer
Fixed airflow obstruction that never fully reverses, in a smoker over 40 who nonetheless has eosinophilia, atopy or a clear asthmatic history, is asthma-COPD overlap — recognised by GINA and GOLD as a pattern, not a separately defined disease — and its management rule is absolute: treat the asthmatic component as the priority, which means an inhaled corticosteroid, always, in combination with a bronchodilator, because long-acting beta-agonist monotherapy in such patients reproduces the excess deaths of the SMART trial era. Long-acting muscarinic antagonists are added on top of steroid-containing therapy, not instead of it. These patients exacerbate more, decline faster and report worse quality of life than either disease alone, so smoking cessation, vaccination and exacerbation prevention carry extra weight, and severe biological therapy remains open to those with type 2 inflammation.
What you must remember
- Recognising the pattern: persistent post-bronchodilator FEV1/FVC below 0.7 with significant but incomplete reversibility, plus asthmatic markers — blood or sputum eosinophils, raised exhaled nitric oxide, atopy, childhood-onset wheeze, or a previous asthma diagnosis — in a smoker or a patient with COPD-risk exposure.
- Epidemiology: up to a quarter of patients with obstructive disease show overlap features, with more exacerbations and higher mortality than either disease alone.
- The non-negotiable rule: inhaled corticosteroid in every overlap patient, combined with a long-acting beta-agonist; LABA alone or LABA-LAMA without a steroid is contraindicated when any asthmatic feature is present.
- Building therapy: ICS-LABA as the foundation, adding a long-acting muscarinic antagonist for triple therapy when symptoms or exacerbations continue; theophylline and roflumilast sit behind these.
- Biologic eligibility persists: overlap patients with eosinophils of 300 or more and recurrent exacerbations despite triple therapy can be considered for type 2 biologics per current guidance, exactly as severe asthma patients are.
- Assessment package: spirometry with reversibility, blood eosinophils, exhaled nitric oxide where available, immunoglobulin E and Aspergillus serology where allergic bronchopulmonary aspergillosis lurks, and a computed tomography chest when bronchiectasis enters the differential — overlap clusters with it.
- Prevention bundle with extra weight: smoking cessation, influenza, pneumococcal and COVID-19 vaccination, pulmonary rehabilitation, and comorbidity care — cardiovascular disease is the leading cause of death in this group, not airflow limitation.
- Indian relevance: overlapping tuberculosis, biomass-fuel smoke exposure and late-diagnosed asthma make overlap disproportionately visible in Indian chest clinics — a stem-writer's staple.
How the exam frames it
The stem describes a 58-year-old smoker with an FEV1/FVC of 0.55, 18 per cent bronchodilator reversibility, eosinophils of 380 and a childhood history of wheeze. The first question is conceptual — is this a separate disease? The answer: no, an overlap pattern without its own criteria, defined by features of both. The second is therapeutic — the option list offers salmeterol-tiotropium (the trap), salmeterol alone (the worse trap), and fluticasone-salmeterol plus tiotropium (the answer). The third is prognostic — more exacerbations, faster decline, worse outcomes than either alone. The fourth tests withdrawal logic: repeated pneumonia or mycobacterial infection on triple therapy — step the steroid down cautiously, never to zero while asthmatic features persist.
A worked example
A 61-year-old bidi smoker has ten years of breathlessness and two admissions last year; spirometry shows FEV1 52 per cent predicted with a ratio of 0.54 improving 16 per cent post-bronchodilator — significant, not normalising. Blood eosinophils are 420, exhaled nitric oxide is marginally raised, and he recalls childhood asthma "treated for years". Step one, name the pattern: asthma-COPD overlap. Step two, apply the rule: medium-dose ICS-LABA immediately — his eosinophil count makes steroid responsiveness likely — and add a muscarinic antagonist for the admission history, giving triple therapy. Step three, treat the COPD half: smoking cessation support (bidi counts as smoking), vaccination, and pulmonary rehabilitation. Step four, review at three months with symptom score and eosinophil re-check: if exacerbations continue with eosinophils above 300, biologic referral is legitimate. Step five, guard the future — cardiac risk assessment and a written exacerbation action plan. Had his eosinophils been 80 with no asthmatic history, he would have remained in the pure COPD file with LABA-LAMA first, and the steroid question would depend on exacerbation frequency alone.
Frequently asked questions
How is asthma-COPD overlap recognised?
Persistent airflow limitation with significant but incomplete reversibility, plus asthmatic features — eosinophilia, atopy, variable symptoms or an asthma history — in a smoker or COPD patient; it is a pattern, not a separately defined disease.
Why must an inhaled corticosteroid always be included?
Long-acting beta-agonist therapy without a steroid increases mortality in asthmatic airway disease — the SMART trial lesson — and overlap patients carry that asthmatic risk.
Which therapy is built first in overlap?
Inhaled corticosteroid plus long-acting beta-agonist as the foundation, escalating to triple therapy by adding a muscarinic antagonist for ongoing symptoms or exacerbations.
Can overlap patients receive asthma biologics?
Yes — those with type 2 inflammation (eosinophils typically 300 or more) and recurrent exacerbations despite triple therapy are considered per current guidance.
How does overlap alter prognosis?
More exacerbations, faster lung-function decline and higher healthcare use than either disease alone — hence the value of naming the pattern.